Hot Biotech Stocks To Own Right Now

Hot Biotech Stocks To Own Right Now: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headq! uartered in Fos t er City, California.

Advisors' Opinion:

• [By alicet236]

  Gilead Sciences Inc (GILD): Chairman and CEO John C Martin sold 140,625 Shares

  Chairman and CEO of Gilead Sciences Inc (GILD) John C Martin sold 140,625 shares on 02/03/2014 at an average price of $79.96. Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. Gilead Sciences Inc has a market cap of $120.75 billion; its shares were traded at around $78.75 with a P/E ratio of 43.10 and P/S ratio of 12.34. Gilead Sciences Inc had an annual average earnings growth of 15.10% over the past 5 years.

• [By Ben Levisohn]

  On a quiet day for big biotech, shares of Celgene have fallen 0.2% to $94.73 at 10:58 a.m., while Amgen (AMGN) has gained 0.1% to $138.69, Gilead Sciences (GILD) has dipped 0.1% to $109.33, Biogen Idec (BIIB) has dropped 0.7% to $34167 and Regeneron (REGN) is off 0.9% at $358.76.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/hot-biotech-stocks-to-own-right-now-2.html